- In 2021, Tryp Therapeutics plans on expanding its academic collaborations
- It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations
- Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and delivery
- A primary objective of the administration of psilocybin is to increase the neuroplasticity of the brain
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently shed light on its operations and the vision that it has both for patients and targeted ailments. In a podcast, Greg McKee, chairman and CEO of the company, candidly shared Tryp’s position on the treatment of diseases with unmet medical needs through the use of psychedelics such as psilocybin (https://ibn.fm/wXQNy).
McKee noted that the company has identified its prospective patients and targeted indications. Narrowing both of these down, he said, allows the company to maintain focus, allowing for the patients’ situations to be adequately served and new solutions to be identified. The company’s primary focus is on chronic pain indications such as fibromyalgia, phantom limb pain, and complex regional pain syndrome, as well as certain eating disorders such as binge eating and hypothalamic obesity.
“All these subcategories of chronic pain are areas where there is a significant unmet medical need. In other words, situations where patients aren’t properly served,” McKee noted (https://ibn.fm/wXQNy).
Tryp Therapeutics is a pharmaceutical company committed to developing compounds for diseases with high unmet medical needs through accelerate regulatory pathways (https://ibn.fm/uk2da). The company sees innovation as being key to addressing patient needs that are not being met by existing treatment options.
“We see that there is a great need to innovate around the specific dose and the specific route of administration [of psychedelic compounds]. Drugs are delivered in a lot of different ways and, up to this point historically, psilocybin and most of the other chemistries in the psychedelics space have all been oral pills,” McKee noted.
Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state. The underlying goal is to increase the brain’s neuroplasticity and encourage proper connectivity among neural networks.
“We’re excited to innovate around the route of administration and controlled dosing so that patients have the proper kind of experience that ultimately addresses their particular illness,” McKee said.
Tryp Therapeutics has created a strong foundation for the identification and treatment of orphan and other diseases. In 2021, the company plans on expanding its academic collaborations and initiating multiple Phase 2a clinical studies to determine the efficacy of its drug products in patient populations. This will be the first time that psilocybin is used for several indications in a clinical trial, marking a significant milestone not just for Tryp Therapeutics but also for psychedelic drug development.
“We anticipate having at least two Phase 2a clinical trials up and running in 2021 and potentially more based on the breadth of academic collaborations we have underway. That will set us up to potentially see signals of efficacy in these patient populations for the first time,” commented McKee (https://ibn.fm/wXQNy).
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.